Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kishor Patel

Internal Medicine Rocky River, OH Medical Doctor

NPI 1073613626 CMS profile 93420

21851 Center Ridge Rd, Suite 405, Rocky River, OH 44116

Open in the dashboard

General payments

$8,013

458 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kishor Patel of Rocky River, OH is reported in the CMS Open Payments database as having received $8,013 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 74
2024 General $1,382 71
2023 General $1,059 64
2022 General $1,245 77
2021 General $1,138 68
2020 General $585 40
2019 General $978 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kishor Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kishor Patel were reported at $1,626. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kishor Patel Internal Medicine median Middle half National median
2019 $978 $159 $48–$570 $163
2020 $585 $119 $33–$402 $114
2021 $1,138 $135 $37–$521 $132
2022 $1,245 $141 $42–$496 $149
2023 $1,059 $149 $45–$519 $160
2024 $1,382 $154 $47–$537 $164
2025 $1,626 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,286 61 payments
  2. Lilly USA, LLC $567 39 payments
  3. Novo Nordisk Inc $417 25 payments
  4. Merck Sharp & Dohme Corporation $310 20 payments
  5. GlaxoSmithKline, LLC. $278 17 payments
  6. Otsuka America Pharmaceutical, Inc. $266 14 payments
  7. Astellas Pharma US Inc $253 13 payments
  8. AbbVie, Inc. $247 18 payments
  9. Novartis Pharmaceuticals Corporation $227 23 payments
  10. Sunovion Pharmaceuticals Inc. $227 15 payments
  11. Other $3,935 213 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,833 453 payments
  2. Education $180 5 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $543 24 payments
  2. BREZTRI $440 17 payments
  3. AIRSUPRA $408 14 payments
  4. Ozempic $344 21 payments
  5. ZENPEP $331 16 payments
  6. VERQUVO $265 18 payments
  7. TRELEGY ELLIPTA $251 15 payments
  8. TRULICITY $236 17 payments
  9. REXULTI $226 12 payments
  10. LOKELMA $217 9 payments
  11. Other $6,192 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 320 drugs

Part D claims

37,987

Median for Internal Medicine: 777

Drug cost

$2,525,217

Median for Internal Medicine: $73,373

Branded share of claims

20.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,078 $502,461
Jardiance Empagliflozin Brand 316 $163,257
Xarelto Rivaroxaban Brand 262 $145,911
Januvia Sitagliptin Phosphate Brand 260 $101,303
Invega Sustenna Paliperidone Palmitate Brand 24 $88,486
Myrbetriq Mirabegron Brand 184 $72,182
Nuedexta Dextromethorphan Hbr/Quinidine Brand 54 $65,533
Ozempic Semaglutide Brand 55 $64,267
Trulicity Dulaglutide Brand 62 $56,580
Linzess Linaclotide Brand 75 $48,778

The 10 drugs with the highest cost, of 320 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$174,578

Medicare's payments for the services billed

Medicare patients

700

Average age 79

Services billed

2,614

390 women, 310 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 36%
Chronic kidney disease 34%
Depression 33%
Diabetes 32%
Atrial fibrillation 31%
Alzheimer's or dementia 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $177
$177 38 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $139
  • Lundbeck LLC $35
$174 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $172
$172 — —
Ozempic
  • Novo Nordisk Inc $87
$87 55 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record